Literature DB >> 17454793

Clinical and epidemiological characteristics of retinoblastoma: correlation with prognosis in a Turkish pediatric oncology center.

Halil Ozdemir1, Nurdan Tacyildiz, Emel Unal, Gulsan Yavuz, Handan Ugur, Kaan Gunduz.   

Abstract

Advanced intraocular tumors and metastatic disease in retinoblastoma patients still occur frequently in developing countries. The aim of this retrospective study was to describe the clinical and epidemiological characteristics of patients with retinoblastoma and the effects of these features on disease prognosis in the authors' pediatric oncology unit as a developing country profile to define the problem. A retrospective chart review of 91 patients who presented to the unit between May 1996 and December 2003 was conducted in this study. Patients with unilateral disease presented at a median age of 24 months and those with bilateral disease at a median age of 9.5 months (p < .01). Most of the eyes with retinoblastoma (68.6%) had Reese-Ellsworth stage V disease. Metastatic disease was diagnosed in 19 (20.9%) patients. Cases with metastatic disease presented at a median age of 24 months and those without metastatic disease at a median age of 12.5 months (p < .05). In 31 patients (34.1%) there was a delay in diagnosis. The enucleation ratio in eyes with advanced intraocular stage was significantly higher than in eyes with early intraocular stage (57.9 vs. 3.8%) (p < .001). In patients with metastatic disease, tumor recurrence was more frequent than in the nonmetastatic patients (36.8 vs. 4.2%) (p < .01). Seven children (7.7%) died due to central nervous system (CNS) metastasis (p < .01). Advanced intraocular disease and distant metastases occur more frequently in Turkish children with retinoblastoma than in children in developed countries, causing a higher rate of enucleation and mortality. Late referral might account for the delayed diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17454793     DOI: 10.1080/08880010601107623

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  7 in total

1.  Compliance in retinoblastoma.

Authors:  Sameer Bakhshi; Shikha Gupta; Varun Gogia; Yaddanapuddi Ravindranath
Journal:  Indian J Pediatr       Date:  2010-03-19       Impact factor: 1.967

2.  Preserving vision in retinoblastoma through early detection and intervention.

Authors:  Sidnei Epelman
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

3.  Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.

Authors:  Duangnate Rojanaporn; Taweevat Attaseth; Wimwipa Dieosuthichat; Kitikul Leelawongs; Samart Pakakasama; Usanarat Anurathapan; Ekachat Chanthanaphak; Sirintara Singhara Na Ayudhaya; Rangsima Aroonroch; Suradej Hongeng
Journal:  J Ophthalmol       Date:  2020-09-10       Impact factor: 1.909

4.  Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma.

Authors:  Marco A Ramírez-Ortiz; M Veronica Ponce-Castañeda; M Lourdes Cabrera-Muñoz; Aurora Medina-Sansón; Xinhua Liu; Manuela A Orjuela
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

5.  "Retinoblastoma survival disparity": The expanding horizon in developing countries.

Authors:  Masood Naseripour
Journal:  Saudi J Ophthalmol       Date:  2012-02-18

6.  Retinoblastoma in the democratic republic of congo: 20-year review from a tertiary hospital in kinshasa.

Authors:  Aimé Kazadi Lukusa; Michel Ntetani Aloni; Bertin Kadima-Tshimanga; Moïse Mvitu-Muaka; Jean Lambert Gini Ehungu; René Ngiyulu; Pépé Ekulu Mfutu; Aléine Budiongo Nzazi
Journal:  J Cancer Epidemiol       Date:  2012-04-26

7.  Characteristics of Germline and Non-germline Retinoblastomas.

Authors:  Fariba Ghassemi; Hormoz Chams; Siamak Sabour; Reza Karkhaneh; Farzad Farzbod; Mehdi Khodaparast; Parvaneh Vosough
Journal:  J Ophthalmic Vis Res       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.